Zoekresultaten - Joshua J. McFarlane
- Toon 1 - 3 resultaten van 3
-
1
-
2
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer door Johanna C. Bendell, Howard S. Höchster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace, Joshua J. McFarlane, Mark Kozloff, Daniel V.T. Catenacci, Jessie J. Hsu, Stephen P. Hack, David S. Shames, See‐Chun Phan, Hartmut Koeppen, Allen Lee Cohn
Gepubliceerd in 2017Artigo -
3
Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study door Nicholas J. Vogelzang, Mark R. Olsen, Joshua J. McFarlane, Edward Arrowsmith, Todd M. Bauer, Rohit Jain, Bradley G. Somer, Elaine T. Lam, Mark D. Kochenderfer, Ana M. Molina, Gurjyot K. Doshi, Brian M. Lingerfelt, Ralph J. Hauke, Vijay Gunuganti, Ian D. Schnadig, Peter J. Van Veldhuizen, Mark T. Fleming, Robert Galamaga, Mukul Kumar Gupta, Hugo Hool, Thomas Hutson, Joshua Zhang, M. Brent McHenry, Jennifer L. Johansen, Scott S. Tykodi
Gepubliceerd in 2020Artigo
Zoekinstrumenten:
Gerelateerde Onderwerpen
Cancer
Gastroenterology
Internal medicine
Medicine
Oncology
Chemotherapy
Clinical endpoint
Colorectal cancer
Environmental health
Population
Adenocarcinoma
Adverse effect
Alternative medicine
Bevacizumab
Chromophobe cell
Clear cell
Clinical trial
Confidence interval
Immunotherapy
Incidence (geometry)
Malignancy
Nivolumab
Odds ratio
Optics
Oxaliplatin
Pathology
Phases of clinical research
Physics
Placebo
Radiation therapy